Shuanghuanglian injection downregulates nuclear factor-kappa B expression in mice with viral encephalitis**

Naibing Gu, Ye Tian, Zhengli Di, Caiping Han, Hui Lei, Gejuan Zhang

Department of Neurology, Xi’an Center Hospital, Xi’an 710003, Shaanxi Province, China

Abstract
A mouse model of viral encephalitis was induced by intracranial injection of a Coxsackie virus B3 suspension. Quantitative real-time reverse transcription-PCR and western blot assay were applied to detect mRNA and protein expression of intelectin-2 and nuclear factor-kappa B in the viral encephalitis and control groups. Nuclear factor-kappa B and intelectin-2 mRNA and protein expression were significantly increased in mice with viral encephalitis. After intraperitoneal injection of Shuanghuanglian at a dose of 1.5 mg/kg for 5 successive days, intelectin-2 and nuclear factor-kappa B protein and mRNA expression were significantly decreased. To elucidate the relationship between intelectin-2 and nuclear factor-kappa B, mice with viral encephalitis were administered an intracerebral injection of $10^7$ pfu recombinant lentivirus expressing intelectin shRNA. Both protein and mRNA levels of intelectin and nuclear factor-kappa B in brain tissue of mice were significantly decreased. Experimental findings suggest that Shuanghuanglian injection may downregulate nuclear factor-kappa B production via suppression of intelectin production, thus inhibiting inflammation associated with viral encephalitis.

Key Words
intelectin; nuclear factor-kappa B; viral encephalitis; short hairpin RNA; Shuanghuanglian injection; mice; lentivirus; nervous system disease; traditional Chinese medicine; neural regeneration

Research Highlights
(1) Expression of intelectin-2 and nuclear factor-kappa B mRNA and protein was significantly increased in brain tissue of mice with viral encephalitis.
(2) Shuanghuanglian injection may downregulate intelectin-2 and nuclear factor-kappa B mRNA and protein expression in brains of viral encephalitis mice.
(3) Intelectin shRNA also decreased intelectin-2 and nuclear factor-kappa B mRNA and protein expression in brains of viral encephalitis mice.
(4) Intelectin is a potential target for the treatment of viral encephalitis.
(5) Shuanghuanglian administration can downregulate nuclear factor-kappa B production via suppression of intelectin production, thus inhibiting inflammation associated with viral encephalitis.

Abbreviations
NF-κB, nuclear factor-kappa B; shRNA, short hairpin RNA
INTRODUCTION

Encephalitis is of public health importance worldwide because of its high morbidity and mortality. However, many details regarding its epidemiology have yet to be elucidated[1]. We observed that nuclear factor-kappa B (NF-κB) expression was significantly increased in mice with viral encephalitis, and *Shuanghuanglian* injection significantly decreased NF-κB protein and mRNA levels[2]. The inhibitory effect was more significant with prolonged intervention duration and increased treatment dose[2]. These findings suggested that *Shuanghuanglian* injection could be therapeutic for viral encephalitis by reducing the expression of NF-κB in a time- and dose-dependent manner[2]. However, the underlying mechanisms of the inhibitory effect of *Shuanghuanglian* injection on NF-κB expression in mice with viral encephalitis remain unclear.

Previous studies showed that intelectin was upregulated in a mouse model of asthma and was required for the production of interleukin-13-induced monocyte chemotactic protein-1 and -3 in mouse lung epithelial cells and contributed to allergic airway inflammation[3]. This indicated that intelectin induced the upregulation of cytokines. Based on a preliminary study, we observed that intelectin and NF-κB expression were significantly increased in mice with viral encephalitis. We hypothesized that intelectin played a role in brain inflammation by regulating cytokine expression.

To test our hypothesis, we examined the kinetics of intelectin and NF-κB expression in a mouse model of viral encephalitis. We administered injection of *Shuanghuanglian* or recombinant lentivirus expressing intelectin short hairpin RNA (shRNA) to mice with viral encephalitis to determine whether intelectin is involved in the upregulation of NF-κB and brain inflammation.

RESULTS

Quantitative analysis of experimental animals

The study used 60 rats and consisted of three parts. First, 20 mice were equally divided into a viral encephalitis model (*n* = 10) or control group (*n* = 10). Second, 20 mice induced for viral encephalitis were equally divided into a model group and *Shuanghuanglian* treatment group. Third, 20 mice with viral encephalitis were equally divided into a model group and shRNA group. Except for the control group, other groups of mice were administered an intracranial injection with Coxsackie virus B3 suspension to induce viral encephalitis. Mice in the *Shuanghuanglian* group and shRNA group were treated with *Shuanghuanglian* injection or lentivirus expressing intelectin shRNA, respectively. A total of 60 mice were involved in the final analysis.

Intelectin-2 and NF-κB were significantly upregulated in the brain of mice with viral encephalitis

We determined the level of intelectin-2 and NF-κB expression in mouse brain after induction of viral encephalitis with Coxsackie virus B3 encephalitis by quantitative real-time reverse transcription-PCR and western blot analysis. Intelectin-2 transcripts were significantly increased in viral encephalitis mice compared with controls (*P* < 0.05; Figure 1). Western blot using an antibody that recognizes identical sequences in intelectin-1 and -2 showed that intelectin protein was significantly increased in mice with viral encephalitis (Figure 1). Similar to intelectin-2 RNA and protein expression, levels of NF-κB transcripts and protein were also increased (*P* < 0.05; Figure 2). Our findings indicated that intelectin-2 and NF-κB mRNA and protein expression were upregulated in the brain tissue of mice with viral encephalitis.

![Figure 1](image-url)  
Expression of intelectin-2 mRNA (A: quantitative real-time reverse transcription-PCR) and protein (B, C: western blot assay) in the brain of viral encephalitis (model group) and normal (control group) mice. Results are expressed as mean ± SEM of 10 mice from each group. *a* P < 0.05, vs. control group. Differences between groups are assessed by two-sample *t*-test.
**Shuanghuanglian injection significantly downregulated intelectin-2 and NF-κB expression in the brain of mice with viral encephalitis**

We next determined whether intelectin was decreased following *Shuanghuanglian* injection. After induction of viral encephalitis, mice were administered *Shuanghuanglian* injection intraperitoneally at a dose of 1.5 mg/kg, once daily, until sacrifice on day 5. We determined intelectin-2 and NF-κB expression by quantitative real-time reverse transcription-PCR and western blot analysis. Intelectin-2 mRNA and protein levels were markedly decreased in mice after *Shuanghuanglian* injection compared with the model group (*P* < 0.05; Figure 3). Simultaneously, protein and mRNA expression levels of NF-κB were significantly downregulated after *Shuanghuanglian* injection (*P* < 0.05; Figure 4). This suggested that intelectin-2 and NF-κB were downregulated in mice after *Shuanghuanglian* treatment.

**Intelectin shRNA treatment significantly decreased intelectin-2 and NF-κB expression in the brain of mice with viral encephalitis**

Based on the above results, we designed the third experimental study to verify the relationship between intelectin and NF-κB. To address this question, we administered intracerebral injection of 10⁷ pfu recombinant lentivirus expressing intelectin shRNA to mice 24 hours after infection with Coxsackie virus B3. Two days after lentivirus injection, mice were sacrificed to harvest brain tissues. Intelectin shRNA transfection inhibited the increase of intelectin-2 and NF-κB transcript and protein levels compared with the model group (*P* < 0.05; Figures 5, 6). Histological analysis revealed that NF-κB positive cells were markedly decreased after intelectin shRNA transfection (*P* < 0.05; Figure 7). This indicated that intelectin was required for the upregulation of NF-κB, and further verified that intelectin is involved in brain inflammation.

**DISCUSSION**

Intelectin was first reported to be expressed in small intestinal Paneth cells in mice⁴. There are two intelectin genes, intelectin-1 and -2, in mice and humans. These genes are highly homologous to a Xenopus oocyte granule lectin⁵-⁶.
The cDNA sequences for mouse intelectin-1 and -2 have 94% homology. Human intelectin-1 is also known as omentin and as intestinal lactoferrin receptor. Since it is found in human omental adipose tissue and can bind to human lactoferrin, human intelectin-1 has been described as a soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell walls, indicating it may play a role in immune defense against bacteria.

NF-κB is a critical protein in the pathogenesis of inflammation, and NF-κB-targeted therapeutics may be effective in treating inflammatory diseases. NF-κB is activated in mouse brain following reovirus infection, which is required for Bid cleavage and subsequent proapoptotic signaling. Coxsackie virus B3 is a strong...
virulent pathogen that has been associated with serious
diseases including myocarditis and encephalitis\cite{14-15}.

Previous studies indicated that Shuanghuanglian
injection has a vital antiviral role in inflammatory
diseases\cite{16-17}. Consistent with this, our previous results
demonstrated that Shuanghuanglian injection inhibited
NF-κB expression\cite{2}; however, the related mechanism by
which Shuanghuanglian downregulated NF-κB expression is unclear. To explore this mechanism, we
designed the following experiments. First, we detected
the level of intelectin-1 and -2 and NF-κB in the brains of
mice with viral encephalitis and the control group.
Second, we assessed the inhibitory effect of
Shuanghuanglian on the expression of intelectin-1 and -2
as well as NF-κB. Third, we observed expression of
intelectin-1 and -2 as well as NF-κB in the brain of mice
with viral encephalitis and treated with intelectin shRNA.
We also analyzed the numbers of NF-κB-positive cells and
levels of NF-κB proteins by western blot assays and
quantitative real-time PCR.

We demonstrated that intelectin-2 and NF-κB were
upregulated in the brain of mice with viral encephalitis
compared with the control group. Protein and mRNA
expression of NF-κB and intelectin-2 were
simultaneously suppressed following treatment with
Shuanghuanglian injection compared with the model
group. These results suggested Shuanghuanglian
injection might decrease NF-κB expression level via
inhibition of intelectin-2 production. Recombinant
lentivirus expressing intelectin shRNA via intracerebral
injection in mice with viral encephalitis downregulated
protein and mRNA levels of intelectin and NF-κB. We
also observed that NF-κB-positive cells were
decreased in the shRNA group compared with the
model group.

These results suggested that Shuanghuanglian
injection exerted a therapeutic effect against viral
encephalitis by inhibiting the activation of NF-κB
through modulating NF-κB gene expression. In addition,
Shuanghuanglian injection decreased the expression of
NF-κB by lowering the expression of intelectin-2. The
study also indicated that intelectin might be involved in
the pathogenesis of viral encephalitis in mice.
Consistent with this, we previously observed that
intelectin was required for increased levels of
inflammatory factors in the genesis and development of
asthmatic airway inflammation\cite{3}.

In summary, this study indicated that Shuanghuanglian
injection exerted antiviral effects through modulating
NF-κB gene expression. This also supports a role for
intelectin in increased expression of NF-κB and brain
inflammation in mice with viral encephalitis. The results
indicate that Shuanghuanglian injection may
downregulate NF-κB expression via suppression of
intelectin production. Thus, intelectin could be a
candidate target for the treatment of viral encephalitis.
Further investigations of the therapeutic utility of
intelectin intervention in animal models of viral
encephalitis are warranted.

**MATERIALS AND METHODS**

**Design**
A randomized, controlled animal experiment.

**Time and setting**
The experiments were performed at the Central
Laboratory of the Fourth Military Medical University of
Chinese PLA between March 2009 and May 2011.
Materials
Sixty healthy, 4-week-old, BALB/c mice, male, weighing 20 ± 2 g, were provided by the Laboratory Animal Center of the Fourth Military Medical University, China (license No. 08-33). The mice were housed at 22 ± 2°C, with 50 ± 5% humidity, and were allowed free access to water and chow. All experimental protocols were conducted in accordance with the Guidance Suggestions for the Care and Use of Laboratory Animals, formulated by the Ministry of Science and Technology of China[18].

Methods
Establishment of a mouse model of viral encephalitis
The modeling procedure was previously described[19-20]. In brief, following anesthesia with ether, the midpoint between the right eye and ear of mice was selected as the injection site. A sharp needle, 0.4 mm in diameter, was inserted perpendicular to the brain at a depth of about 3 mm. Mice in the viral encephalitis group were intracranially injected with 20 µL of 4.5 × 10⁸ pfu of a Coxsackie virus B3 suspension (Wuhan Institute of Virology, Chinese Academy of Sciences, Hubei Province, China), which was propagated in HeLa cells (Tongji Medical College, Huazhong University of Science and Technology, China) and titrated as previously described[21]. Mice from the control group were injected with 20 μL of saline. Clinical manifestations were monitored daily and scored as follows[22]: 0, no detectable sign of disease; 1, ruffled fur; 2, slightly hunched back and ruffled fur; 3, very hunched back and lethargy; and 4, death. Mice that were successfully infected and scored between 1–3 points were included in the study.

Shuanghuanglian treatment
After establishment of the viral encephalitis model, some mice were intraperitoneally injected with Shuanghuanglian at dose of 1.5 mg/kg[2] (a compound powder for injection; main components include Honeysuckle Flower, Radix Scutellariae and Fructus Forsythiae; National Medicine Permit No. Z23021513; Harbin Pharmaceutical Co., Ltd., Harbin, Heilongjiang Province, China), once daily, until sacrifice (a total of 5 days). Mice from the model group were injected with 20 µL of saline, once daily. The two groups were sacrificed on day 5.

Administration of lentivirus expressing intelectin shRNA
Mice in the shRNA group were administered an intracerebral injection of 10⁷ pfu recombinant lentivirus expressing intelectin shRNA (Tongji Medical College, Huazhong University of Science and Technology, China) 1 day after injection with Coxsackie virus B3 suspension. Intelectin shRNA significantly inhibited the basal level of both intelectin-1 and -2 transcripts[3]. The control model group was administered an empty plasmid. The two groups were sacrificed on day 3.

Tissue specimens
After abdominal anesthesia by chloral hydrate, mice brains were harvested. Brain tissues were incubated in 4% formalin for 24 hours for immunohistochemistry. Mice brains were isolated and stored at –80°C until used for western blot analysis.

Quantitative real-time reverse transcription-PCR for intelectin-2 and NF-κB mRNA expression
Total RNA from mouse brains was isolated using TRizol (Invitrogen Life Technologies, Carlsbad, CA, USA). First-strand cDNA synthesis was performed using PrimeScript RT reagent kit (Takara, Tokyo, Japan). SYBR Green real-time PCR was performed for mouse intelectin-2 and NF-κB using Perfect Real Time kit (Takara). Real-time PCR was performed using SYBR Premix Ex Taq polymerase (Takara) and Rotor-Gene 3000 (Corbett Research, Sydney, Australia). Two-step PCR amplification conditions are as follows: step 1: pre-denaturing, (95°C for 10 seconds, 20°C/s, 1 cycle); step 2: PCR reaction (95°C for 5 seconds, 20°C/s; 60°C for 20 seconds, 20°C/s; 40 cycles). The cycle threshold of each mouse gene transcript was normalized to the Ct of mouse β-actin. Fold differences were determined by the 2⁻ⁿCt method[23]. The primer sequences are as follows:

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sequences (5’–3’)</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intelectin-2</td>
<td>Upstream: GCG CTT GGG CCA TAA TCT GT</td>
<td>270</td>
</tr>
<tr>
<td></td>
<td>Downstream: CGG CCA GAG GGA GAG TAA TAA</td>
<td></td>
</tr>
<tr>
<td>NF-κB</td>
<td>Upstream: CAA TGG CTA CAC AGG ACC A</td>
<td>320</td>
</tr>
<tr>
<td></td>
<td>Downstream: CAC TGT CAC CTG GAA CCA GA</td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td>Upstream: ATC ATG TTT GAG ACC TTC AAG A</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>Downstream: CAT CTC TTG CTC GAA GTC CA</td>
<td></td>
</tr>
</tbody>
</table>

Western blot analysis for intelectin-2 and NF-κB protein expression
Mouse brain tissue was harvested at the indicated time points, washed twice with cold PBS, and lysed in Mammalian Protein Extraction Reagent with phenylmethylsulfonyl fluoride (Pierce Biotechnology Inc., Rockford, IL, USA). Protein concentrations were determined using the Bradford method[24]. After
15 minutes on ice, lysates were centrifuged at 15 000 × g for 15 minutes to remove insoluble material. 50 µg of protein samples were resolved by 10% SDS-PAGE, transferred and immuno-probed with chicken anti-mouse monoclonal antibody against intelectin (1:750), and incubated for 12 hours at 4.0°C. The intelectin antibody (Division of Veterinary Clinical Sciences, University of Edinburgh, Roslin, UK) was raised against a peptide containing a sequence that is completely conserved between mouse intelectin-1 and -2. The antibody was detected using peroxidase-conjugated rabbit anti-chicken IgY (1:5 000; Sigma, St. Louis, MO, USA; incubating for 1 hour at room temperature) followed by ECL (Pierce Biotechnology). Blots were stripped and then reprobed for rabbit anti β-actin polyclonal antibody (1:1 000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). For NF-κB western blot analysis, rabbit anti-mouse NF-κB monoclonal antibody (1:250; Serotec, Oxford, UK) was used. The antibody was detected with peroxidase-conjugated goat anti-rabbit IgG (1:1 000; Zhongshan Golden Bridge Biotechnology, Beijing, China). Densitometry was performed using Image J (National Institutes of Health, Bethesda, MD, USA) and the protein levels of intelectin and NF-κB were indexed to β-actin (data were shown as relative absorbance).

**Immunohistochemistry for NF-κB-positive cells in brain tissues**

Mouse brain tissue was fixed for 5 minutes by instillation of 4% paraformaldehyde-PBS (Sigma) overnight and cut to 2-mm-thick coronal slices. Slices including the injection site were embedded in paraffin and further sliced at a thickness of 5 µm. In accordance with the streptavidin-biotin-peroxidase complex method, 5-µm-thick sections were used for immunohistochemistry with rabbit anti-mouse monoclonal antibody against NF-κB (1:250; Serotec; incubating for 12 hours at 4.0°C). Peroxidase-conjugated goat anti-rabbit IgG (1:1 000; Zhongshan Golden Bridge Biotechnology) was used as the secondary antibody (incubating for 30 minutes at 37.0°C). Antibodies were detected using the DAB kit (Zhongshan Golden Bridge Biotechnology) as directed by the manufacturer. Finally, the distribution of NF-κB-positive cells was observed using a light microscope (BH-2; Olympus, Tokyo, Japan).

Five visual fields (× 400) from each of five sections from each mouse were randomly selected for quantification of NF-κB-positive cells and total cells. The mean values were also calculated. The ratio of NF-κB-positive cells was calculated as the mean number of NF-κB-positive cells/the total number of cells observed. As a negative control, PBS was used in place of the primary antibody, and identical procedures were performed on serial sections.

**Statistical analysis**

Data were analyzed using SPSS 13.0 software (SPSS, Chicago, IL, USA). Experimental data are presented as mean ± SEM. Differences between groups were assessed by two-sample t-test. A P value < 0.05 was considered statistically significant.

**Acknowledgments:** We are very grateful to Dr. Alan Pemberton (Division of Veterinary Clinical Sciences, University of Edinburgh, Roslin, UK) for kindly providing the intelectin antibody.

**Funding:** This study was funded by the Health Research Fund from the Health Department of Shaanxi Province, China, No. 04015.

**Author contributions:** This study was designed and performed by Naibing Gu, and completed with the technical support of Gejuan Zhang and Hui Lei. The data were analyzed by Ye Tian. The manuscript was written by Zhengli Di, and revised by Caiping Han.

**Conflicts of interest:** None declared.

**Ethical approval:** This study was permitted by the Animal Ethics Committee of Fourth Military Medical University of Chinese PLA.

**Author statements:** The manuscript is original, has not been submitted to or is not under consideration by another publication, has not been previously published in any language or any form, including electronic, and contains no disclosure of confidential information or authorship/patent application disputations.

**REFERENCES**


(Edited by Yang Y/Song LP)